Macquarie Group’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.52M Buy
61,075
+3,239
+6% +$271K 0.02% 387
2026
Q1
$4.63M Sell
57,836
-53,432
-48% -$4.41M 0.03% 363
2025
Q4
$9.49M Sell
111,268
-1,116,898
-91% -$91.7M 0.04% 299
2025
Q3
$95.5M Buy
1,228,166
+160,478
+15% +$12.5M 0.11% 241
2025
Q2
$83.5M Buy
1,067,688
+873,042
+449% +$65.1M 0.1% 283
2025
Q1
$14.1M Buy
194,646
+45,660
+31% +$3.27M 0.02% 741
2024
Q4
$9.34M Sell
148,986
-3,771
-2% -$264K 0.01% 820
2024
Q3
$10.1M Sell
152,757
-1,678,559
-92% -$122M 0.01% 819
2024
Q2
$169M Sell
1,831,316
-35,043
-2% -$3.1M 0.19% 126
2024
Q1
$178M Sell
1,866,359
-133,921
-7% -$11.2M 0.2% 119
2023
Q4
$153M Sell
2,000,280
-34,431
-2% -$2.4M 0.18% 146
2023
Q3
$141M Buy
2,034,711
+328,211
+19% +$26.4M 0.18% 144
2023
Q2
$161M Buy
1,706,500
+19,440
+1% +$1.69M 0.18% 141
2023
Q1
$140M Sell
1,687,060
-605,178
-26% -$47.6M 0.17% 164
2022
Q4
$171M Buy
2,292,238
+208,090
+10% +$16M 0.2% 118
2022
Q3
$172M Buy
2,084,148
+653,969
+46% +$62.9M 0.21% 106
2022
Q2
$136M Sell
1,430,179
-136,134
-9% -$14.1M 0.15% 167
2022
Q1
$184K Sell
1,566,313
-106,921
-6% -$12M 0.14% 150
2021
Q4
$217M Sell
1,673,234
-37,524
-2% -$4.38M 0.18% 132
2021
Q3
$194M Sell
1,710,758
-166,487
-9% -$19M 0.17% 144
2021
Q2
$194M Buy
1,877,245
+257,857
+16% +$24.3M 0.16% 146
2021
Q1
$135M Sell
1,619,388
-104,912
-6% -$8.87M 0.19% 115
2020
Q4
$157M Buy
1,724,300
+254,030
+17% +$21.1M 0.23% 93
2020
Q3
$117M Buy
1,470,270
+1,162,530
+378% +$90.7M 0.2% 100
2020
Q2
$21.3M Sell
307,740
-9,975
-3% -$709K 0.04% 448
2020
Q1
$20M Sell
317,715
-23,292
-7% -$1.68M 0.04% 417
2019
Q4
$26.5M Buy
341,007
+233,565
+217% +$18.2M 0.04% 436
2019
Q3
$7.88M Sell
107,442
-9,087
-8% -$638K 0.01% 650
2019
Q2
$7.18M Sell
116,529
-8,235
-7% -$498K 0.01% 685
2019
Q1
$7.96M Sell
124,764
-48,708
-28% -$2.78M 0.01% 669
2018
Q4
$8.86M Sell
173,472
-14,610
-8% -$739K 0.02% 615
2018
Q3
$10.9M Buy
188,082
+28,650
+18% +$1.4M 0.02% 624
2018
Q2
$7.74M Sell
159,432
-8,907
-5% -$416K 0.01% 683
2018
Q1
$7.83M Sell
168,339
-41,550
-20% -$1.8M 0.01% 662
2017
Q4
$7.77M Buy
209,889
+1,872
+0.9% +$68.7K 0.01% 691
2017
Q3
$7.58M Sell
208,017
-91,383
-31% -$3.49M 0.01% 670
2017
Q2
$11.8M Sell
299,400
-88,173
-23% -$3.22M 0.02% 568
2017
Q1
$12.2M Sell
387,573
-60,567
-14% -$1.9M 0.02% 570
2016
Q4
$14M Buy
448,140
+162,588
+57% +$5.27M 0.03% 531
2016
Q3
$11.5M Sell
285,552
-147,450
-34% -$5.55M 0.02% 565
2016
Q2
$14.4M Buy
433,002
+210,102
+94% +$7.19M 0.01% 638
2016
Q1
$6.55M Sell
222,900
-79,500
-26% -$2.19M 0.01% 652
2015
Q4
$7.96M Buy
302,400
+24,900
+9% +$647K 0.02% 598
2015
Q3
$6.58M Buy
277,500
+255,300
+1,150% +$6.16M 0.01% 649
2015
Q2
$527K Hold
22,200
﹤0.01% 1289
2015
Q1
$527K Hold
22,200
﹤0.01% 1255
2014
Q4
$471K Hold
22,200
﹤0.01% 1278
2014
Q3
$378K Hold
22,200
﹤0.01% 1307
2014
Q2
$318K Sell
22,200
-1,800
-8% -$24.4K ﹤0.01% 1375
2014
Q1
$297K Hold
24,000
﹤0.01% 1359
2013
Q4
$263K Buy
24,000
+8,400
+54% +$94.7K ﹤0.01% 1363
2013
Q3
$181K Sell
15,600
-109,800
-88% -$1.28M ﹤0.01% 1427
2013
Q2
$1.41M Buy
+125,400
New +$1.48M ﹤0.01% 1060

Other funds holding EW

Macquarie Group's EW Position: Q2 2026 in Review

Macquarie Group increased its Edwards Lifesciences (EW) stake by 5.6% in Q2 2026, buying an estimated $271K and bringing the position to 61,075 shares worth $5.52M. The position accounts for 0.02% of the portfolio, ranked #387.

Macquarie Group first reported a position in EW in Q2 2013 and has held it in 53 quarters since. The position peaked at $217M in Q4 2021. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Macquarie Group held 61,075 shares of Edwards Lifesciences worth $5.52M as of Q2 2026.
  • Macquarie Group bought 3,239 Edwards Lifesciences shares in Q2 2026, an estimated $271K.
  • Edwards Lifesciences made up 0.02% of Macquarie Group's portfolio in Q2 2026, its #387 holding.
  • Macquarie Group first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 53 quarters since.
  • Macquarie Group's Edwards Lifesciences position peaked at $217M in Q4 2021.
  • 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Macquarie Group's 13F filing for Q2 2026, filed 14 Aug 2026.